|
|
Article: Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas.
- Article from:
- PR Newswire
- Article date:
- May 22, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BETHESDA, Md., May 22 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that the company will provide an update on the phase 1 clinical trial underway for its BiTE(R) antibody MT103/MEDI-538 at the 10th International Conference on Malignant Lymphomas, taking place June 4-7 in Lugano, Switzerland.
The presentation, entitled, "Anti-CD19 BiTE Antibody MT103 (MEDI-538) Induces Durable Objective Responses in Patients with Relapsed Non-Hodgkin's Lymphoma (NHL). Update from Ongoing Phase I Study MT103-104" will take place ...